Cargando…

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey

To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobashi, Yurie, Kawamura, Takeshi, Shimazu, Yuzo, Zhao, Tianchen, Sugiyama, Akira, Nakayama, Aya, Kaneko, Yudai, Nishikawa, Yoshitaka, Omata, Fumiya, Takita, Morihito, Yamamoto, Chika, Yoshida, Makoto, Kosaka, Makoto, Murayama, Anju, Sugiura, Sota, Tanaka, Manato, Kawashima, Moe, Uchi, Yuna, Shindo, Joji, Oikawa, Tomoyoshi, Shibuya, Kenji, Kodama, Tatsuhiko, Tsubokura, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640658/
https://www.ncbi.nlm.nih.gov/pubmed/36344597
http://dx.doi.org/10.1038/s41598-022-21797-x
_version_ 1784825906155487232
author Kobashi, Yurie
Kawamura, Takeshi
Shimazu, Yuzo
Zhao, Tianchen
Sugiyama, Akira
Nakayama, Aya
Kaneko, Yudai
Nishikawa, Yoshitaka
Omata, Fumiya
Takita, Morihito
Yamamoto, Chika
Yoshida, Makoto
Kosaka, Makoto
Murayama, Anju
Sugiura, Sota
Tanaka, Manato
Kawashima, Moe
Uchi, Yuna
Shindo, Joji
Oikawa, Tomoyoshi
Shibuya, Kenji
Kodama, Tatsuhiko
Tsubokura, Masaharu
author_facet Kobashi, Yurie
Kawamura, Takeshi
Shimazu, Yuzo
Zhao, Tianchen
Sugiyama, Akira
Nakayama, Aya
Kaneko, Yudai
Nishikawa, Yoshitaka
Omata, Fumiya
Takita, Morihito
Yamamoto, Chika
Yoshida, Makoto
Kosaka, Makoto
Murayama, Anju
Sugiura, Sota
Tanaka, Manato
Kawashima, Moe
Uchi, Yuna
Shindo, Joji
Oikawa, Tomoyoshi
Shibuya, Kenji
Kodama, Tatsuhiko
Tsubokura, Masaharu
author_sort Kobashi, Yurie
collection PubMed
description To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort. Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained. Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90–120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities. Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy.
format Online
Article
Text
id pubmed-9640658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96406582022-11-14 Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey Kobashi, Yurie Kawamura, Takeshi Shimazu, Yuzo Zhao, Tianchen Sugiyama, Akira Nakayama, Aya Kaneko, Yudai Nishikawa, Yoshitaka Omata, Fumiya Takita, Morihito Yamamoto, Chika Yoshida, Makoto Kosaka, Makoto Murayama, Anju Sugiura, Sota Tanaka, Manato Kawashima, Moe Uchi, Yuna Shindo, Joji Oikawa, Tomoyoshi Shibuya, Kenji Kodama, Tatsuhiko Tsubokura, Masaharu Sci Rep Article To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort. Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained. Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90–120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities. Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy. Nature Publishing Group UK 2022-11-07 /pmc/articles/PMC9640658/ /pubmed/36344597 http://dx.doi.org/10.1038/s41598-022-21797-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kobashi, Yurie
Kawamura, Takeshi
Shimazu, Yuzo
Zhao, Tianchen
Sugiyama, Akira
Nakayama, Aya
Kaneko, Yudai
Nishikawa, Yoshitaka
Omata, Fumiya
Takita, Morihito
Yamamoto, Chika
Yoshida, Makoto
Kosaka, Makoto
Murayama, Anju
Sugiura, Sota
Tanaka, Manato
Kawashima, Moe
Uchi, Yuna
Shindo, Joji
Oikawa, Tomoyoshi
Shibuya, Kenji
Kodama, Tatsuhiko
Tsubokura, Masaharu
Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
title Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
title_full Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
title_fullStr Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
title_full_unstemmed Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
title_short Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
title_sort humoral immunity after second dose of bnt162b2 vaccine in japanese communities: an observational cross-sectional study, fukushima vaccination community survey
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640658/
https://www.ncbi.nlm.nih.gov/pubmed/36344597
http://dx.doi.org/10.1038/s41598-022-21797-x
work_keys_str_mv AT kobashiyurie humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT kawamuratakeshi humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT shimazuyuzo humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT zhaotianchen humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT sugiyamaakira humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT nakayamaaya humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT kanekoyudai humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT nishikawayoshitaka humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT omatafumiya humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT takitamorihito humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT yamamotochika humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT yoshidamakoto humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT kosakamakoto humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT murayamaanju humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT sugiurasota humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT tanakamanato humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT kawashimamoe humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT uchiyuna humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT shindojoji humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT oikawatomoyoshi humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT shibuyakenji humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT kodamatatsuhiko humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey
AT tsubokuramasaharu humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey